{"id":"quetiapine-fumarate-or-valproate","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Sedation/somnolence"},{"rate":"15-30","effect":"Weight gain"},{"rate":"10-20","effect":"Dizziness"},{"rate":"5-15","effect":"Tremor"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"1-3","effect":"Hepatotoxicity (valproate)"},{"rate":"<1","effect":"Pancreatitis (valproate)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Quetiapine fumarate antagonizes dopamine and serotonin receptors, reducing psychotic symptoms and stabilizing mood. Valproate increases GABA levels and modulates histone deacetylase activity, providing mood stabilization and anticonvulsant effects. The combination targets both psychotic and mood symptoms in psychiatric disorders.","oneSentence":"This is a combination of two distinct psychiatric medications: quetiapine fumarate (an atypical antipsychotic) and valproate (a mood stabilizer), each working through different neurochemical pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:02.232Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar disorder (acute mania or mixed episodes)"},{"name":"Schizophrenia"},{"name":"Major depressive disorder with psychotic features"}]},"trialDetails":[{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT04513314","phase":"PHASE4","title":"Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2023-03-28","conditions":"Covid19, Hyperactive Delirium, Pneumonia, Viral","enrollment":""},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT01588457","phase":"PHASE4","title":"Sequential Multiple Assignment Treatment for Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-06","conditions":"Bipolar I Disorder, Bipolar II Disorder","enrollment":112},{"nctId":"NCT00397020","phase":"PHASE4","title":"Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-12","conditions":"Bipolar Disorder","enrollment":30},{"nctId":"NCT00183443","phase":"PHASE3","title":"Treatment of Mania Symptoms With Drug Therapy","status":"COMPLETED","sponsor":"Palo Alto Veterans Institute for Research","startDate":"2005-02","conditions":"Bipolar Disorder, Schizophrenia","enrollment":75},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01893229","phase":"PHASE4","title":"Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania","status":"UNKNOWN","sponsor":"Guiyun Xu","startDate":"2013-09","conditions":"Bipolar Disorder","enrollment":120},{"nctId":"NCT00208819","phase":"PHASE4","title":"A Comparison of Two Standard Therapies in the Management of Dementia With Agitation","status":"COMPLETED","sponsor":"Emory University","startDate":"2003-09","conditions":"Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease","enrollment":50},{"nctId":"NCT00114686","phase":"PHASE3","title":"Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-01","conditions":"Bipolar I Disorder, Alcohol Dependence","enrollment":350},{"nctId":"NCT00107731","phase":"PHASE3","title":"Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":"Bipolar I Disorder","enrollment":710},{"nctId":"NCT00081380","phase":"PHASE3","title":"Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-03","conditions":"Bipolar Disorder","enrollment":710},{"nctId":"NCT00254774","phase":"PHASE3","title":"Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-01","conditions":"Bipolar Disorder","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15426,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"quetiapine fumarate or valproate","genericName":"quetiapine fumarate or valproate","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two distinct psychiatric medications: quetiapine fumarate (an atypical antipsychotic) and valproate (a mood stabilizer), each working through different neurochemical pathways. Used for Bipolar disorder (acute mania or mixed episodes), Schizophrenia, Major depressive disorder with psychotic features.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}